The yin and the yang of immunosuppression with inhaled corticosteroids

Thorax

Volumn 68, Issue 12, 2013, Pages 1085-1087

  Sabroe, Ian ^a,b   Postma, Dirkje ^c   Heijink, Irene ^c   Dockrell, David H ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; SALMETEROL; TUMOR NECROSIS FACTOR ALPHA;

ASTHMA; ATYPICAL MYCOBACTERIOSIS; BACTERIAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DRUG MEGADOSE; EDITORIAL; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; INFECTION RISK; LUNG ALVEOLUS MACROPHAGE; MYCOBACTERIOSIS; NONHUMAN; PHAGOCYTOSIS; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; TUBERCULOSIS;

ASTHMA; COPD EXACERBATIONS;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ASTHMA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG; MYCOBACTERIUM INFECTIONS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84887503251     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2013-203773     Document Type: Editorial

References (19)

1. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89 (Pubitemid 46294610)
2. Chaudhuri N, Whyte MKB, Sabroe I. Reducing the toll of inflammatory lung disease. Chest 2007;131:1550-6 (Pubitemid 46762365)
3. Dockrell DH, Whyte MKB, Mitchell TJ. Pneumococcal pneumonia: mechanisms of infection and resolution. Chest 2012;142:482-91
4. Fieschi C, Dupuis S, Catherinot E, et al. Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor beta1 deficiency: medical and immunological implications. J Exp Med 2003;197:527-35 (Pubitemid 36278607)
5. Marriott HM, Daigneault M, Thompson AAR, et al. A decoy receptor analogue reduces localised defects in phagocyte function in pneumococcal pneumonia. Thorax 2012;67:985-92
6. Crim C, Calverley PMA, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34:641-7
7. Ernst P, Gonzalez AV, Brassard P, et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;176:162-6 (Pubitemid 47057852)
8. Andréjak C, Nielsen R, Thomsen V, et al. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax 2013;68:256-62
9. Brassard P, Suissa S, Kezouh A, et al. Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. Am J Respir Crit Care Med 2011;183:675-8
10. Lee CH, Kim K, Hyun MK, et al. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax 2013;68:1105-13
11. Marshall BG, Wangoo A, Harrison LI, et al. Tumour necrosis factor-alpha production in human alveolar macrophages: modulation by inhaled corticosteroid. Eur Respir J 2000;15:764-70 (Pubitemid 30196307)
12. O?Sullivan S, Cormincan L, Burke CM, et al. Fluticasone induces T cell apoptosis in the bronchial wall of mild to moderate asthmatics. Thorax 2004;59:657-61 (Pubitemid 39061527)
13. Johnston S. Overview of virus-induced airway disease. Proc Am Thorac Soc 2005;2:150-6 (Pubitemid 41233383)
14. Wark PA, Johnston SL, Bucchieri F, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 2005;201:937-47 (Pubitemid 40524463)
15. Heijink IH, van den Berge M, Jonker MR, et al. Comparing the effects of fluticasone propionate and budesonide on airway epithelial barrier function. Am J Respir Crit Care Med 2012;185:A6796
16. Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol-Lung C 2007;293:L660-7 (Pubitemid 47358828)
17. Halpin DMG, Gray J, Edwards SJ, et al. Budesonide/ formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. Int J Clin Pract 2011;65:764-74
18. Didierlaurent A, Goulding J, Patel S, et al. Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. J Exp Med 2008;205:323-9 (Pubitemid 351281598)
19. Zhang N, Truong-Tran QA, Tancowny B, et al. Glucocorticoids enhance or spare innate immunity: effects in airway epithelium are mediated by CCAAT/ enhancer binding proteins. J Immunol 2007;179:578-89. (Pubitemid 46986575)